|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|
| Deferred offering costs | |||||
| Current assets: | |||||
| Due from Sponsor | |||||
| Cash and cash equivalents | |||||
| Prepaid insurance | |||||
| Prepaid expenses and other current assets | |||||
| Total current assets | |||||
| Marketable securities held in Trust Account | |||||
| Long-term prepaid insurance | |||||
| TOTAL ASSETS | |||||
| Current liabilities: | |||||
| Accrued expenses | |||||
| Accrued offering costs | |||||
| Due to related party | |||||
| Promissory note - related party | |||||
| Total current liabilities | |||||
| Deferred underwriting fee payable | |||||
| Total Liabilities | |||||
| Class A ordinary shares subject to possible redemption, 17,250,000 at redemption value of $10.35 and $10.27 at March 31, 2026 and December 31, 2025, respectively | |||||
| Shareholders’ Deficit | |||||
| Ordinary shares, value | |||||
| Additional paid-in capital | |||||
| Accumulated deficit | |||||
| Total Shareholders’ Deficit | |||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
